Scinai Immunotherapeutics Announces Receipt of a Nasdaq Staff Determination Letter Regarding Shareholders Equity listing requirements and Hearing to Present a Plan for Regaining Compliance prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
The Board has Approved a Ratio Change of the ADSs to Non-traded Ordinary Shares Designed to Regain Compliance JERUSALEM, ISRAEL -May 6th, 2024 - Scinai.
Scinai Immunotherapeutics : The Board has Approved a Ratio Change of the ADSs to Non-traded Ordinary Shares (equivalent to a reverse split) Designed to Regain Compliance - Form 6-K marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.
/PRNewswire/ Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI), a biopharmaceutical company focused on developing inflammation and immunology (I&I) biological.
Scinai Immunotherapeutics CDMO Unit Selected by Ayana Pharma to Provide Drug Development and cGMP Manufacturing Services tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.